Skip to main content
SpringerLink
Log in

Management of marginal zone lymphomas

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Marginal-zone lymphoma (MZL) includes three subtypes depending on the site of lymphoma involvement: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma); splenic MZL; and nodal MZL. Although there is a common cell of origin and similarities concerning a possible chronic antigenic stimulation by microbial pathogens and/or auto-antigens, the clinical presentation is very different with symptoms related to lymphoma location. MALT and splenic MZL present with an indolent disease with good performance status, no B symptoms, and no adverse prognostic factors and are associated with long survival. Patients with nodal MZL present with a shorter progression-free survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The optimal treatment has yet to be defined for the three subtypes, and current strategies are described in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Maes B, De Wolf-Peeters C: Marginal zone cell lymphoma-an update on recent advances. Histopathology 2002, 40:117–126.

    Article  PubMed  CAS  Google Scholar 

  2. Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 1994, 84:1361–1392.

    PubMed  CAS  Google Scholar 

  3. Jaffe ES, Harris NL, Stein H, Vardiman JW: World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2001.

    Google Scholar 

  4. Mulligan SP, Matutes E, Dearden C, Catovsky D: Splenic lymphoma with villous lymphocytes. Natural history and response to therapy in 50 cases. Br J Haematol 1991, 78:206–209.

    PubMed  CAS  Google Scholar 

  5. Troussard X, Valensi F, Duchayne E, et al.: Splenic lym-phoma with villous lymphocytes: clinical presenta-tion, biology and prognostic factors in a series of 100 patients. Groupe Francais d'Hematologie Cellulaire (GFHC). Br J Haematol 1996, 93:731–736.

    Article  PubMed  CAS  Google Scholar 

  6. Thieblemont C, Felman P, Callet-Bauchu E, et al.: Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003, 4:95–103.

    Article  PubMed  CAS  Google Scholar 

  7. Nathwani B, Anderson J, Armitage J, et al.: Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999, 17:2486–2492.

    PubMed  CAS  Google Scholar 

  8. Berger F, Felman P, Thieblemont C, et al.: Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000, 95:1950–1956.

    PubMed  CAS  Google Scholar 

  9. Farinha P, Gascoyne R: Helicobacter pylori and MALT lymphoma. Gastroenterology 2005, 128:1579–1605.

    Article  PubMed  CAS  Google Scholar 

  10. Cerroni L, Zochling N, Putz B, Kerl H: Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997, 24:457–461.

    Article  PubMed  CAS  Google Scholar 

  11. Lecuit M, Abachin E, Martin A, et al.: Immunoprolifera-tive small intestinal disease associated with Campylo-bacter jejuni. N Engl J Med 2004, 350:239–248.

    Article  PubMed  CAS  Google Scholar 

  12. Ferreri A, Guidoboni M, Ponzoni M, et al.: Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004, 96:586–594.

    Article  PubMed  Google Scholar 

  13. Zucca E, Conconi A, Pedrinis E, et al.: Nongastric mar-ginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003, 101: 2489–2495.

    Article  PubMed  CAS  Google Scholar 

  14. Arcaini L, Paulli M, Boveri E, et al.: Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer 2004, 100:107–115.

    Article  PubMed  Google Scholar 

  15. Bates I, Bedu-Addo G: Chronic malaria and splenic lymphoma: clues to understanding lymphoma evolu-tion. Leukemia 1997, 11 : 2162–2167.

    Article  PubMed  CAS  Google Scholar 

  16. Pinotti G, Zucca E, Roggero E, et al.: Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 1997, 26:527–537.

    PubMed  CAS  Google Scholar 

  17. Thieblemont C, Bastion Y, Berger F, et al.: Mucosa-asso-ciated lymphoid tissue gastrointestinal and non-gastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997, 15:1624–1630.

    PubMed  CAS  Google Scholar 

  18. Thieblemont C, Berger F, Dumontet C, et al.: Mucosa-associated lymphoid tissue lymphoma is a dissemi-nated disease in one third of 158 patients analyzed. Blood 2000, 95:802d-806d.

    Google Scholar 

  19. Copie-Bergman C, Gaulard P, Lavergne-Slove A, et al.: Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 2003, 52:1656.

    Article  PubMed  CAS  Google Scholar 

  20. Conconi A, Martinelli G, Thieblemont C, et al.: Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003, 15:2741–2745.

    Article  CAS  Google Scholar 

  21. Wotherspoon A, Doglioni C, Diss T, et al.: Regression of primary low-grade B-cell gastric lymphoma of mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993, 342:575–577. This is the first report of a lymphoma regression obtained by antibiotics. This key reference leads to build the “MALT concept.≓

    Article  PubMed  CAS  Google Scholar 

  22. Wundisch T, Thiede C, Morgner A, et al.: Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005, 23:8018–8024.

    Article  PubMed  Google Scholar 

  23. Roggero E, Zucca E, Mainetti C, et al.: Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000, 31: 263–268.

    Article  PubMed  CAS  Google Scholar 

  24. Bertoni F, Conconi A, Capella C, et al.: Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 2002, 99:2541–2544

    Article  PubMed  CAS  Google Scholar 

  25. Tsang R, Gospodarowicz M, Pintilie M, et al.: Stage I and II MALT lymphoma: results of treatment with radio-therapy. Int J Radiat Oncol Biol Phys 2001, 50:1258–1264.

    Article  PubMed  CAS  Google Scholar 

  26. Schechter N, Portlock C, Yahalom J: Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998, 16:1916–1921.

    PubMed  CAS  Google Scholar 

  27. Hammel P, Haioun C, Chaumette M, et al.: Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995, 13:2524–2529.

    PubMed  CAS  Google Scholar 

  28. Martinelli G, Laszlo D, Ferreri A, et al.: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helico-bacter pylori therapy. J Clin Oncol 2005, 23:1979–1983.

    Article  PubMed  CAS  Google Scholar 

  29. Radaszkiewicz T, Dragosics B, Bauer P: Gastrointestinal malignant lymphomas of the mucosa-associated lym-phoid tissue: factors relevant to prognosis. Gastroenter-ology 1992, 102: 1628–1638.

    CAS  Google Scholar 

  30. Montalban C, Castrillo J, Abraira V, et al.: Gastric B-cell mucosa-associated lymphoid tissue (MALT) lym-phoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol 1995, 6:355–362.

    PubMed  CAS  Google Scholar 

  31. Baens M, Maes B, Steyls A, et al.: The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 2000, 156:1433–1439.

    PubMed  CAS  Google Scholar 

  32. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al.: Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradi-cation therapy. Lancet 2001, 357:39–40.

    Article  PubMed  CAS  Google Scholar 

  33. Levy M, Copie-Bergman C, Gameiro C, et al.: Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005, 23:5061–5066.

    Article  PubMed  Google Scholar 

  34. Thieblemont C, Felman P, Berger F, et al.: Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma 2002, 3:41–47.

    Article  PubMed  Google Scholar 

  35. Talamini R, Montella M, Crovatto M, et al.: Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004, 110 : 380–385.

    Article  PubMed  CAS  Google Scholar 

  36. Hermine O, Lefrere F, Bronowicki J, et al.: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002, 11 : 89–94. The authors describe the first series of patients treated with an antiviral therapy, inducing a lymphoma regression.

    Article  Google Scholar 

  37. Chacon J, Mollejo M, Munoz E, et al.: Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002, 100:1648–1654.

    PubMed  CAS  Google Scholar 

  38. Catovsky D, Matutes E: Splenic lymphoma with circu-lating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999, 36:148–154.

    PubMed  CAS  Google Scholar 

  39. Franco V, Florena A, Stella M, et al.: Splenectomy influ-ences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001, 91: 294–301

    Article  PubMed  CAS  Google Scholar 

  40. Lefrere F, Hermine O, Belanger C, et al.: Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000, 14:573–575.

    Article  PubMed  CAS  Google Scholar 

  41. Lefrere F, Hermine O, Francois S, et al.: Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000, 40:113–11 7.

    Article  PubMed  CAS  Google Scholar 

  42. Camacho FI, Mollejo M, Mateo MS, et al.: Progression to large B-cell lymphoma in splenic marginal zone lymphoma--a description of a series of 12 cases. Am J Surg Pathol 2001, 25:1268–1276.

    Article  PubMed  CAS  Google Scholar 

  43. Neubauer A, Thiede C, Morgner A, et al.: Cure of Helico-bacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997, 89:1350–1355.

    Article  PubMed  CAS  Google Scholar 

  44. Berger F: The different entities and diagnostic problems. Educational Program of the European Hematology Association Meeting. Birmingham, UK, June 25–28, 2000.

  45. Koh L, Lim L, Thng C: Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 2000, 17:225–228.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'hematologie clinique, Centre Hospitalier Lyon-Sud, Pavillon 1F, F-69495, Pierre-Benite Cedex, France

    Bertrand Coiffier MD, PhD

Authors
  1. Catherine Thieblemont MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bertrand Coiffier MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thieblemont, C., Coiffier, B. Management of marginal zone lymphomas. Curr. Treat. Options in Oncol. 7, 213–222 (2006). https://doi.org/10.1007/s11864-006-0014-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-006-0014-9

Keywords

Search

Navigation